CoQ10 may be beneficial in migraines.





Related Monographs

Consumer Data: Coenzyme Q10 (CO-Q10) Migraine
Professional Data: Coenzyme Q10 (CO-Q10) Migraine


As anyone who has experienced one knows, there is absolutely nothing like a migraine headache. A migraine headache can be debilitating for hours and sometimes for days. The migraine headache is considered a vascular headache, although the precise mechanism and cause remain unknown. There are several known triggers, some of which include food allergies, blood sugar disturbances, stress load, mechanical injury, and hormonal fluctuations. Treating a migraine means working with these triggers.

Migraine may be classified as migraine without aura, formerly called common migraine, or migraine with aura, formerly known as classic migraine. The differences are based upon the presence or absence of neurologic symptoms prior to the onset of headache. The aura may consist of flashing lights, or zigzag lines, or may manifest as blind spots in the vision. Some people even experience speech difficulty, tingling in the face or hands, confusion, or weakness of an arm or leg. The majority of people suffering from classic migraine have an aura that develops 10-30 minutes prior to development of the actual headache. According to recent studies, the aura is believed to be the response to a trigger that creates a neuronal depression. This may result in as much as a 25-35 percent reduction in cerebral blood flow, and is certainly enough to cause the symptoms associated with the aura.

A recent study investigated the use of CoEnzyme Q10 (CoQ10) as a preventative measure against migraines. 26 women and 6 men that had a history of migraines (with or without auras) were recruited for this study. Each person took 150 mg of CoQ10 a day. At baseline, migraines occurred in these individuals an average of 7.34 days out of a month. After 3 months of therapy, the average occurrence of migraines had dropped significantly to 2.95 days every month. The results showed that 61.3 % had over a 50% reduction in the prevalence of migraines. In the first month of CoQ10 treatment, migraine incidence was only reduced by 13%, but by the end of the 3rd month, the incidence had decreased 55.3%. In addition, there were no side effects reported with the use of CoQ10. The authors stated that it is now time to investigate the efficacy of CoQ10 in placebo-controlled trials.1


1. Rozen TD, et al. Open label trial of Coenzyme Q10 as a migraine preventive. Cephalalgia. May 2002;22(2):137.